This issue’s illustrations are from the article “CA 15-3-specific molecularly imprinted polymer nanoparticles-based voltammetric sensor for breast cancer monitoring” published on February 16, 2025, in Talanta (IF 5.6).
1. CA 15-3 specific nano molecularly imprinted polymers (nanoMIPs) have been developed and used as recognition sites for CA 15-3 detection;
2. The combination of nanoMIPs with electrochemical detection methods has been successfully applied for the detection of CA 15-3;
3. This method enables quantitative detection of CA 15-3, which can be used for monitoring and follow-up of breast cancer patients.
Conclusion
By combining CA 15-3 specific nanoMIPs with electrochemical sensors, this technology demonstrates significant potential in breast cancer monitoring devices.
Background Supplement
The level of CA 15-3 in serum can serve as a potential biomarker for breast cancer monitoring. Molecularly imprinted polymers (MIPs) are referred to as “artificial antibodies” used to mimic natural antibodies, and solid-phase synthesis can produce molecularly imprinted polymer nanoparticles (nanoMIPs). The combination of nanoMIPs with electrochemical analysis offers advantages such as high selectivity, high sensitivity, chemical stability, ease of preparation, low cost, and high stability. The synthesized nanoMIPs are immobilized on modified electrodes and serve as binding sites for CA 15-3, demonstrating significant utility in breast cancer treatment and monitoring.
References:
https://doi.org/10.1016/j.talanta.2025.127746
Previous Recommendations
Illustrated Breast ‘Donation’ | Issue 065: Dual-target Inhibitors of STAT3 and NQO1 for Breast Cancer Treatment
Illustrated Breast ‘Donation’ | Issue 064: Intratumoral Bacteria in Breast Cancer and Intervention Strategies
Illustrated Breast ‘Donation’ | Issue 063: Different Cellular Mechanisms of Chemotherapy Combined with PD-L1 Blockade in Triple-Negative Breast Cancer
Editor: Ariel
Typesetting: KIKI
Execution: Uni
Yilaitong is a professional online doctor platform, with the mission of “perceiving the pulse of world medicine and assisting clinical decision-making in China.” Yilaitong has a series of products including ‘Clinical Guidelines’, ‘Medication Reference’, ‘Medical Literature King’, ‘Medical Knowledge Source’, ‘e-Research’, ‘e-Pulse Broadcast’, etc., to comprehensively meet the needs of medical professionals for clinical decision-making, acquiring new knowledge, and improving research efficiency.
This platform aims to deliver more medical information to healthcare professionals. The content published on this platform should not replace professional medical guidance in any way and should not be considered as medical advice. If such information is used for purposes other than understanding medical information, this platform does not assume any related responsibility. The content published on this platform does not represent agreement with its descriptions and viewpoints. If there are copyright issues, please contact us, and we will handle it promptly.
